HealthCare – PLUSS®

Lifesciences & Healthcare

Essential Newborn Care – Temperature controlled Pharma & Biological product logistics

Helped save over 30 million vaccines

Saving lives of 20,000+ babies in India every year

Good health and wellbeing is third of the seventeen Sustainable Development Goals (SDGs) established by United Nations.

Plusstainibility at Work

Plusstainability to us is to channelize the concepts of thermal energy in promoting good health and wellbeing for the most vulnerable sections of the society. Thermal energy when stored in Phase Change Materials provides energy access for essential newborn care as well as for temperature sensitive lifesaving drugs and vaccines.

Pluss pre-validates its solutions using Smart CAE(computer aided engineering) – a cutting-edge software adapted to simulate performance of thermal packaging solutions equipped with phase-change materials (PCMs) enabling over 80% reduction in energy, fuel and wastage of packaging material on developmental cycle.

Essential NewBorn Care

More than 650,000 newborns die every year of birth asphyxia, second largest cause of neonatal deaths, and 90% of these deaths are in developing countries with deliveries made in low resource setting. Therapeutic hypothermia, which is controlled cooling at 33.5° C, is the only clinically proven method to treat asphyxiated babies. PLUSS’ patented and award-winning device, MiraCradle® Neonate Cooler, made cooling simpler, efficient and ten times more affordable than the standard equipments. Based on advanced Phase Change Material (PCM) technology the device is safe, validated, CE approved, non-electric and reusable, giving healthcare access to those who need it the most.

MiraCradle^® at Work

• Saving lives of 20,000+ babies in India every year and deterring the onset of debilitating conditions like autism and cerebral palsy.

• Only clinically proven system for treating birth asphyxia by inducing therapeutic hypothermia even in low resource countries

• World’s most affordable system based on patented Phase Change Material (PCM) technology.

• Installed at over hundreds of hospitals in India and worldwide

To download brochure click here

Optimizing Vaccine Efficiency

Studies estimate that over 30% vaccines are
wasted every year for cold-chain issues.

India has emerged as a global pharmaceutical hub of R&D, manufacturing and consumption. The Indian pharma market now stands at over $30 billion, with the highest number of sites approved by the US Food and Drug Administration (FDA) after the US itself. India produces and runs world’s largest immunization programs. However, with more and more complex drug molecules being worked upon, right temperature comes out as one of the most important factors for the stability of vaccines or medicines. Ensuring that they reach country’s health care distribution system in the right condition is a considerable challenge.

Freezing of vaccines and potency loss

All vaccines lose potency over time, and the rate of loss is temperature dependent – both at higher as well as freezing temperature. Liquid vaccines that contain aluminum salt adjuvants are more vulnerable to freezing temperature than heating. Diphtheria toxoid, tetanus toxoid, pertussis, liquid Haemophilus influenzae type b, hepatitis A, hepatitis B, human papillomavirus, liquid Japanese Encephalitis, liquid meningococcal, liquid pneumococcal, liquid rabies vaccines, inactivated polio and influenza vaccines are all freeze sensitive. Many of the newer vaccines being introduced in the immunization program including some of the COVID-19 vaccines are also freeze sensitive. Freezing can irreversibly compromise vaccine potency and leave a vaccinated child unprotected. Most vaccine carriers being used in the immunization programs today carry a high risk of exposing the vaccines to freezing temperatures. Vaccines when packed in the carrier are directly exposed to ice packs that are frozen at -20°C freezer. Without a proper mechanism and right systems, this is difficult to manage and control.

Celsure^® Temperature Controlled
Packaging for Pharmaceuticals
and Biological Products

PLUSS has developed, validated and patented, 100% indigenously made temperature-controlled packaging – Celsure^®, based on tenets of thermal energy storage using PCM technology. A vast range of PCMs (from -65°C to +89°C) allows PLUSS to successfully maintain temperature at different points for up to 120 hours (five days). The choice with the industry was between a non-validated, imprecise, but low-cost gel-pack based packaging vs. validated, imported but high-cost packaging. Celsure^® presents a third option – precise, validated and affordable.

To download brochure click here

Celsure^® Temperature Controlled
Packaging Benefits

Helped save over 30 million vaccines and counting
Provides precise temperature between 2° to 8° C, 15° to 25°C , <-20° C, and ultra-low (<-60°C),
Pre-validated against International Standards (ISTA 7D/ WHO)
Easier to use and faster to assemble - as less as in 5 minutes